Abstract
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight- Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Keywords: CSPG4, immunotherapy, monoclonal antibody, cancer stem cells
Current Molecular Medicine
Title: CSPG4 in Cancer: Multiple Roles
Volume: 10 Issue: 4
Author(s): X. Wang, Y. Wang, L. Yu, K. Sakakura, C. Visus, J.H. Schwab, C.R. Ferrone, E. Favoino, Y. Koya, M.R. Campoli, J.B. McCarthy, A.B. DeLeo and S. Ferrone
Affiliation:
Keywords: CSPG4, immunotherapy, monoclonal antibody, cancer stem cells
Abstract: Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight- Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Export Options
About this article
Cite this article as:
Wang X., Wang Y., Yu L., Sakakura K., Visus C., Schwab J.H., Ferrone C.R., Favoino E., Koya Y., Campoli M.R., McCarthy J.B., DeLeo A.B. and Ferrone S., CSPG4 in Cancer: Multiple Roles, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791316977
DOI https://dx.doi.org/10.2174/156652410791316977 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Sulfation of Drug Compounds by the Zebrafish Cytosolic Sulfotransferases (SULTs)
Drug Metabolism Letters Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate
Letters in Drug Design & Discovery Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2
Current HIV Research Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry